Zoetis (NYSE: ZTS)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Zoetis Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Zoetis Company Info
Veterinary pharma company spun off from Pfizer.
News & Analysis
Your returns would be the cat's meow, to say the least.
This stock is a proven long-term play, but it's struggling lately.
Sluggish growth and multiple headwinds weighed on the stock.
Analysts think these stocks can rise by 40% or more from their current levels.
Zoetis' business is generally stable and very consistent -- but the same can't be said for its struggling stock.
These stocks could have significant upside opportunities ahead.
These stocks are down, but they're definitely not out.
Two of the biggest names in animal care continue to grow.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 02/07/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
ZTS earnings call for the period ending September 30, 2022.
ZTS earnings call for the period ending June 30, 2022.
ZTS earnings call for the period ending March 31, 2022.
ZTS earnings call for the period ending December 31, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.